Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 80 50 versus TRICHLOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 80 50 versus TRICHLOREX.
INDERIDE LA 80/50 vs TRICHLOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of propranolol (non-selective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Trichlorex is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
One capsule orally once daily, containing propranolol hydrochloride 80 mg (immediate release) and hydrochlorothiazide 50 mg. May be titrated based on response, with maximum propranolol dose 640 mg/day and maximum hydrochlorothiazide dose 50 mg/day.
Oral: 500 mg once daily after the evening meal; sustained-release: 500 mg once daily at bedtime.
None Documented
None Documented
Propranolol: 3-6 hours (poor metabolizers up to 10 hours). Hydrochlorthiazide: 6-15 hours (prolonged in renal impairment).
Terminal elimination half-life is 8-12 hours in adults; prolonged to 20-30 hours in severe renal impairment (creatinine clearance <30 mL/min).
Renal elimination of propranolol and hydrochlorthiazide: propranolol is extensively metabolized in the liver, <1% excreted unchanged in urine; hydrochlorthiazide is excreted unchanged in urine (≥95% renal).
Renal (90% as unchanged drug, 10% as trichloroacetic acid and trichloroethanol); minor biliary/fecal (less than 1%).
Category C
Category C
Beta Blocker and Thiazide Diuretic
Thiazide Diuretic